Amoxicillin-clavulanate is one of the most frequently used antibiotics in emergency departments and primary care offices throughout the country. It is a combination of two separate drugs: amoxicillin and clavulanic acid. Amoxicillin is a penicillin derivative and has similar activity against both gram-positive and gram-negative bacteria, including Enterococcus species, Listeria monocytogenes, Streptococcus species, Haemophilus influenzae, Moraxella catarrhalis, Corynebacterium diphtheria, Escherichia coli, Klebsiella pneumoniae, Salmonella, Shigella, and Borrelia species. Furthermore, with the addition of clavulanic acid, the spectrum is increased to include all beta-lactamase-producing strains of the previously mentioned organisms, as well as broadening the coverage to include methicillin-sensitive Staphylococcus aureus, Neisseria species, Proteus species, Pasteurella multocida, and Capnocytophaga canimorsus, among others.
Amoxicillin-clavulanate has FDA approval for the treatment of aspiration pneumonia, community-acquired pneumonia, acute bacterial rhinosinusitis, urinary tract infections, acute otitis media, and skin and soft tissue infections. Off-label uses include the treatment of human or animal bite wounds, group A streptococcal infections, impetigo, acute exacerbations of chronic obstructive pulmonary disease and bronchiectasis, diabetic foot infections, odontogenic infections, and peritonsillar cellulitis/abscess.
Amoxicillin is a broad-spectrum beta-lactam antibiotic, originally derived from penicillin. It is a bactericidal agent that targets and kills bacteria by inhibiting the biosynthesis of the peptidoglycan layer of the bacterial cell wall. This layer makes up the outermost portion of the cell wall and is responsible for the structural integrity of the cell. Peptidoglycan synthesis involves the facilitation of enzymes called DD-transpeptidases, which are a type of penicillin-binding protein (PBP). Amoxicillin works by binding to these PBPs and inhibiting peptidoglycan synthesis, which interrupts the construction of the cell wall and ultimately leads to the destruction, or lysis, of the bacteria.
Clavulanic acid is a beta-lactamase inhibitor often used in conjunction with amoxicillin to broaden its spectrum further and combat resistance. It has little to no antimicrobial activity of its own and instead works by preventing bacterial destruction of antibiotics. Over the years, certain bacteria have evolved to develop resistance to standard beta-lactam antibiotics through the production of enzymes called beta-lactamases. These enzymes target and hydrolyze the beta-lactam ring, which is necessary for penicillin-like antibiotics to work. Clavulanic acid prevents this degradation by binding and deactivating the beta-lactamases, thus restoring the antimicrobial effects of amoxicillin.
Amoxicillin-clavulanate is only available in oral formulations and like most bactericidal antibiotics, needs to be administered at regularly scheduled intervals to minimize differences in the antibiotic’s peaks and troughs. This approach helps maintain consistent serum concentrations over the minimum inhibitory concentration (MIC) needed to destroy the targeted organism effectively; this is generally accomplished by a twice or three times daily administration of the medication. Oral formulations of this antibiotic are available as immediate or extended-release tablets, reconstituted suspensions, or chewable tablets. The reconstituted solution should be kept in the refrigerator and shaken well before the administration to maximize its longevity and effectiveness. It is recommended to take this antibiotic with food to enhance its absorption as well as minimize any adverse GI symptoms.
Amoxicillin-clavulanate is largely safe and well-tolerated in the general population, with the vast majority of adverse effects being only mild gastrointestinal symptoms. The single most common complaint is diarrhea, but others include nausea, vomiting, loose stools, and abdominal discomfort. Of note, the incidence of diarrhea is higher in amoxicillin-clavulanate compared with amoxicillin alone. Additionally, there is a moderately increased risk of secondary Clostridium difficile colitis when compared with other classes of antibiotics. Females taking this medication can also develop vaginitis secondary to vaginal mycosis or candidiasis.
Dermatologic effects are less common and generally related to hypersensitivity reactions. These reactions can present anywhere on the spectrum of disease, ranging from simple pruritis or urticaria to severe and life-threatening manifestations, such as anaphylaxis, Steven-Johnson syndrome, or toxic epidermal necrolysis. Classically, a morbilliform rash will present shortly after initiation of amoxicillin in patients misdiagnosed as strep pharyngitis, when, in fact, they have infectious mononucleosis.
Very rare complications of amoxicillin-clavulanate use include prolonged prothrombin time, vasculitis, thrombocytopenia, cholestatic jaundice, elevated serum alkaline phosphatase, hepatitis, and hepatotoxicity.
Caution is warranted when treating patients on hemodialysis or with severe renal impairment with creatinine clearance less than 30 mL/minute. As this antibiotic primarily gets renally excreted, individuals with renal disease will need dose adjustments and closer monitoring.
There are no guidelines for dosing in hepatic impairment, but extreme caution is necessary when considering use in this population. This medication is contraindicated in any patient with a prior history of amoxicillin or clavulanic acid-induced hepatic dysfunction.
Lastly, use in patients with previous hypersensitivity reactions to amoxicillin, clavulanic acid, or other beta-lactam antibiotics is also contraindicated. As amoxicillin is a penicillin derivative, there is a high likelihood of crossover hypersensitivity in patients with a documented penicillin allergy. In this population, clinicians should consider alternative antibiotic options.
Patients taking amoxicillin-clavulanate require monitoring at the beginning of therapy for signs of hypersensitivity and throughout the course for signs of secondary infection, such as C. difficile colitis or candidiasis. Prolonged therapy, or use greater than 10 to 14 days, will also require intermittent monitoring of hepatic, renal, and hematologic function. Patients with hepatic impairment should receive regular monitoring of liver enzymes up to several weeks after discontinuation of the antibiotic.
Although amoxicillin-clavulanate is an excellent antibiotic, it is one of the most frequent causes of idiosyncratic drug-induced hepatic injury. Men are at increased risk when compared to women, as well as patients greater than 50 years of age. Other factors include genetic polymorphisms, HIV patients on antiretroviral therapy, or concomitant use of medications that influence the cytochrome P450 pathway. Time of symptom onset is generally 2 to 3 weeks after the initial dose, but may occur more rapidly or even be delayed up to 12 weeks. Treatment involves immediate discontinuation of the offending agent and limiting the use of other hepatotoxic drugs. N-acetylcysteine and corticosteroids are also considerations; however, the benefits are likely marginal. Administration of a bile acid sequestrant, such as cholestyramine, may provide symptomatic relief from pruritis. Full recovery, although prolonged, is achieved by the majority of patients; however, a select few will go on to develop liver failure requiring a liver transplant to survive.
All drug-related reactions, including drug-induced hepatic injury, pose a real threat to society and have the potential to lead to significant morbidity or mortality if not appropriately identified and managed. Open and effective interprofessional communication is essential among all members of the medical team. Proper management begins in the primary care office or emergency department with physicians maintaining broad differentials and a high index of suspicion through clinical gestalt and information gained from a thorough history and physical exam. Appropriate investigative tests then need to be ordered and properly interpreted to identify possible drug reactions as the explanation for a patient’s presenting symptoms. In the case of drug-induced hepatic injury secondary to antibiotic use, a patient will likely present with liver injury days to weeks after completing a course of antibiotics, and a direct correlation may not be straightforward. If there is suspicion for drug-induced hepatic injury, identifying and discontinuing the offending agent is the main goal of treatment. [Level I] The involvement of a specialist, such as a hepatologist, can be beneficial, especially when there is a concern for acute liver failure, chronic liver disease, or the diagnosis remains unclear after the initial evaluation. Furthermore, in patients with evidence of liver failure or who are at high risk, early transport to liver transplant facilities can be advantageous. [Level I] Other treatment modalities include corticosteroids and N-acetylcysteine. However, the benefits are likely marginal, and their use should be in conjunction with a specialist. [Level III]
In summary, proactive instead of reactive methods are always more valuable. Proper antibiotic stewardship can decrease unnecessary use of antibiotics, and therefore reduce the incidence of drug-related adverse effects as well as limit the rate of antibiotic resistance. This stewardship is but one aspect of amoxicillin-clavulanate management by an interprofessional team. Information sharing between emergency medicine and primary care physicians can further help with early identification of suspected adverse reactions as well as improve appropriate antibiotic selection for individuals who must undergo treatment. The pharmacist can weigh in by checking dose and duration, providing antibiogram data, and checking for drug interactions that may interfere with therapy. Nursing can administer the medication, counsel the patient on proper administration, and monitor for adverse events and therapeutic effectiveness. When a severe adverse reaction has occurred, the early involvement of a specialist can limit the severity of disease and increase the chance of a full and uneventful recovery. All these exemplify the actions of an interprofessional team approach that improves the odds of optimal patient outcomes [Level V]
|||Brogden RN,Carmine A,Heel RC,Morley PA,Speight TM,Avery GS, Amoxycillin/clavulanic acid: a review of its antibacterial activity, pharmacokinetics and therapeutic use. Drugs. 1981 Nov; [PubMed PMID: 7037354]|
|||Benninger MS, Amoxicillin/clavulanate potassium extended release tablets: a new antimicrobial for the treatment of acute bacterial sinusitis and community-acquired pneumonia. Expert opinion on pharmacotherapy. 2003 Oct; [PubMed PMID: 14521493]|
|||Bucher HC,Tschudi P,Young J,Périat P,Welge-Lüussen A,Züst H,Schindler C, Effect of amoxicillin-clavulanate in clinically diagnosed acute rhinosinusitis: a placebo-controlled, double-blind, randomized trial in general practice. Archives of internal medicine. 2003 Aug 11-25; [PubMed PMID: 12912714]|
|||Jacobs MR, Extended release amoxicillin/clavulanate: optimizing a product for respiratory infections based on pharmacodynamic principles. Expert review of anti-infective therapy. 2005 Jun; [PubMed PMID: 15954852]|
|||White AR,Kaye C,Poupard J,Pypstra R,Woodnutt G,Wynne B, Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. The Journal of antimicrobial chemotherapy. 2004 Jan; [PubMed PMID: 14726431]|
|||Iravani A,Richard GA, Treatment of urinary tract infections with a combination of amoxicillin and clavulanic acid. Antimicrobial agents and chemotherapy. 1982 Oct; [PubMed PMID: 7181477]|
|||Fleisher GR,Wilmott CM,Campos JM, Amoxicillin combined with clavulanic acid for the treatment of soft tissue infections in children. Antimicrobial agents and chemotherapy. 1983 Nov; [PubMed PMID: 6660847]|
|||Marchant CD,Shurin PA,Johnson CE,Murdell-Panek D,Feinstein JC,Fulton D,Flexon P,Carlin SA,Van Hare GF, A randomized controlled trial of amoxicillin plus clavulanate compared with cefaclor for treatment of acute otitis media. The Journal of pediatrics. 1986 Nov; [PubMed PMID: 3534203]|
|||Abrahamian FM, Dog Bites: Bacteriology, Management, and Prevention. Current infectious disease reports. 2000 Oct; [PubMed PMID: 11095891]|
|||Antimicrobial prophylaxis in surgery. The Medical letter on drugs and therapeutics. 2001 Oct 29; [PubMed PMID: 11689761]|
|||Dajani A,Taubert K,Ferrieri P,Peter G,Shulman S, Treatment of acute streptococcal pharyngitis and prevention of rheumatic fever: a statement for health professionals. Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, the American Heart Association. Pediatrics. 1995 Oct; [PubMed PMID: 7567345]|
|||Stein GE,Gurwith MJ, Amoxicillin-potassium clavulanate, a beta-lactamase-resistant antibiotic combination. Clinical pharmacy. 1984 Nov-Dec; [PubMed PMID: 6391783]|
|||Wise R,Andrews JM,Bedford KA, In vitro study of clavulanic acid in combination with penicillin, amoxycillin, and carbenicillin. Antimicrobial agents and chemotherapy. 1978 Mar; [PubMed PMID: 122520]|
|||Bax R, Development of a twice daily dosing regimen of amoxicillin/clavulanate. International journal of antimicrobial agents. 2007 Dec; [PubMed PMID: 17983732]|
|||Mulroy R, Amoxycillin rash in infectious mononucleosis. British medical journal. 1973 Mar 3; [PubMed PMID: 4266345]|
|||Thompson DF,Ramos CL, Antibiotic-Induced Rash in Patients With Infectious Mononucleosis. The Annals of pharmacotherapy. 2017 Feb; [PubMed PMID: 27620494]|
|||Ónodi-Nagy K,Kinyó Á,Meszes A,Garaczi E,Kemény L,Bata-Csörgő Z, Amoxicillin rash in patients with infectious mononucleosis: evidence of true drug sensitization. Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology. 2015; [PubMed PMID: 25784943]|
|||Thong BY, Update on the management of antibiotic allergy. Allergy, asthma [PubMed PMID: 20358021]|
|||deLemos AS,Ghabril M,Rockey DC,Gu J,Barnhart HX,Fontana RJ,Kleiner DE,Bonkovsky HL, Amoxicillin-Clavulanate-Induced Liver Injury. Digestive diseases and sciences. 2016 Aug; [PubMed PMID: 27003146]|
|||Chalasani NP,Hayashi PH,Bonkovsky HL,Navarro VJ,Lee WM,Fontana RJ, ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. The American journal of gastroenterology. 2014 Jul; [PubMed PMID: 24935270]|
|||Evans CM,Purohit S,Colbert JW,Lear PA,Makin T,Scobie DJ,Williamson EP,Sells RA, Amoxycillin-clavulanic acid (Augmentin) antibiotic prophylaxis against wound infections in renal failure patients. The Journal of antimicrobial chemotherapy. 1988 Sep; [PubMed PMID: 3053562]|
|||Hussaini SH,Farrington EA, Idiosyncratic drug-induced liver injury: an overview. Expert opinion on drug safety. 2007 Nov [PubMed PMID: 17967156]|
|||Giordano C,Rivas J,Zervos X, An Update on Treatment of Drug-Induced Liver Injury. Journal of clinical and translational hepatology. 2014 Jun [PubMed PMID: 26356645]|
|||Polson J,Lee WM, AASLD position paper: the management of acute liver failure. Hepatology (Baltimore, Md.). 2005 May [PubMed PMID: 15841455]|